News
Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...
1d
Zacks.com on MSNHere's What to Expect From Pfizer's Non-Oncology Drugs in Q2 EarningsPFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings ...
Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...
Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients. The list price for Eliquis (apixaban) is ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...
17h
24/7 Wall St. on MSNI Am Buying 5 Blue-Chip Dividend Stocks That Have Been Crushed in 2025These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.
The health landscape sees pivots as companies adjust strategies: Bristol Myers and Pfizer offer discounts on Eliquis, Newcastle University's IVF technique prevents genetic diseases, and Juul's ...
Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...
A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.
Pharmaceutical companies have been in talks with the U.S. government to figure out how to bring drug prices down after President Trump signed in May an executive order that ties U.S. prices to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results